glp-1 drugs pharmaceutical companies news 2025 Beyond GLP-1: the next wave of weight-loss medication innovation fda compounding glp-1 enforcement news

Oral formulations are advancing rapidly

Although nNOS and eNOS are mainly expressed steadily in neurons and endothelial cells regardless of the cell's metabolic state, iNOS exists in trace amounts under healthy conditions and is synthesized de novo in some immunological cells, such as microglia, via inflammatory triggering (32)

4.7.3 SCFAs may alleviate GERD symptoms by supporting immune homeostasis and reducing inflammation SCFA, especially butyrate, can alter the secretion of pro-inflammatory mediators (e.g., interferon (IFN) - (IL-1, IL-2, IL-6, IL-8, tumor necrosis factor (TNF) - ) by a possible mechanism through inhibition of NF-B in intestinal epithelial cells (96, 97)

Farquhar, G